Resources Repository
-
BookPublication 1980Clinical Decision Analysis
This text was conceived and developed in the Harvard T.H. Chan School of Public Health …
This text was conceived and developed in the Harvard T.H. Chan School of Public Health at the Center for the Analysis of Health Practices. The book had its origins in a set of classroom materials developed during the academic year 1974-75 for an elective course in medical decision making at the Harvard Medical School. In this book students are shown how to structure clinical decision problems, how to systematically formulate the intertwining roles of diagnosis and treatment, how to…
Preferences/Values | Probability/Bayes | Test Performance | Cost-Effectiveness Analysis | Decision Analysis | Economics/Finance | Chronic Disease/Risk | Costing Methods | Health Outcomes | Value of Information | State-Transition | Infectious Diseases | Child/Nutrition | Health/Medicine | Global | North America | Europe | Graduate | Doctoral | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
ReportPublication 2017Economic Value of Informal Mental Health Caring
Caregivers, family and friends play a significant role in supporting people with mental illness, and …
Caregivers, family and friends play a significant role in supporting people with mental illness, and it has long been recognized that informal carers constitute a significant ‘hidden’ workforce in Australia. Faced as Australia is with an ageing population and burgeoning chronic disease, data on the contribution that carers make and the consequent savings to governments and other ‘payers’ need to be articulated. This report attempts to put a ‘value’ on informal caring for those with mental illness.…
Preferences/Values | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Economics/Finance | Chronic Disease/Risk | Costing Methods | Health Outcomes | Mental Health | Health Systems | Health/Medicine | Oceania -
ArticlePublication 2016Challenges of Prioritization
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and …
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and diagnostics; in addition, the evidence base drawn on for evaluating such interventions is relatively good, given the medical research industry surrounding their testing. However, with increasing success in controlling infectious diseases, many of the health challenges facing countries concern broad threats to health with multiple causes, such as obesity, where the relationship between policy action and health benefit is not…
Priority Setting/Ethics | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Economics/Finance | Chronic Disease/Risk | Infectious Diseases | Mental Health | Health Systems | Health/Medicine | Global -
ArticlePublication 2016An Economic Evaluation of the PEN Program in Indonesia
Responding to the economic and health burden of noncommunicable diseases (NCDs), the World Health Organization (WHO) …
Responding to the economic and health burden of noncommunicable diseases (NCDs), the World Health Organization (WHO) introduced the Package of Essential Noncommunicable disease (PEN) interventions. Several countries, including Indonesia, implemented the PEN program. To assess the value of the investment in the current program, an economic evaluation of the program was conducted with collaboration between the Ministry of Health in Indonesia, the WHO, and the International Decision Support Initiative (iDSI). This study evaluated the delivery of…
Priority Setting/Ethics | Technology Assessment | Cost-Effectiveness Analysis | Economics/Finance | Chronic Disease/Risk | Health Systems | Government/Law | Health/Medicine | Asia & Pacific -
ArticlePublication 2022Health and Financial Risk Protection Outcomes in Economic Evaluations
Extended cost-effectiveness analysis was developed to evaluate health interventions in terms of level and distribution …
Extended cost-effectiveness analysis was developed to evaluate health interventions in terms of level and distribution of health gains and financial risk protection. This information is typically presented in a joint display format. This article develops and applies an algebraic money-metric formulation that incorporates all disaggregated outcomes and finds that ranking of health interventions is sensitive to the decision maker’s aversion to inequality across income groups and that financial risk protection gains are most important to…
Priority Setting/Ethics | Cost-Effectiveness Analysis | Economics/Finance | Chronic Disease/Risk | Social Determinants | Health/Medicine | Global -
ArticlePublication 2016Health and Economic Benefits of Public Financing of Epilepsy Treatment in India
This study uses extended cost-effectiveness analysis (ECEA) to evaluate the impact of three scenarios of …
This study uses extended cost-effectiveness analysis (ECEA) to evaluate the impact of three scenarios of publicly financed national epilepsy programs in India that provide (1) first line antiepilepsy drugs (AEDs), (2) first- and second-line AEDs, and (3) first- and second-line AEDs and surgery. Outcome measures include disability-adjusted life years (DALYs) averted, and cost per DALY averted. Economic benefit measures estimated include out-of-pocket (OOP) expenditure averted and money-metric value of insurance. All three scenarios represent a…
Priority Setting/Ethics | Cost-Effectiveness Analysis | Economics/Finance | Chronic Disease/Risk | Microsimulation | Health/Medicine | Asia & Pacific -
ReportPublication 2017DCP3: Improving Health and Reducing Poverty
This report from the World Bank is the ninth and final volume of the Disease …
This report from the World Bank is the ninth and final volume of the Disease Control Priorities, Third Edition (DCP3) series. It provides an overview of the findings and methods explored in the first eight volumes, placing them within a framework that identifies an efficient pathway toward essential universal health coverage through the implementation of 21 essential packages that include health interventions and fiscal and intersectoral policies. The Disease Control Priorities Network (DCP) promotes and…
Benefit-Cost Analysis | Cost-Effectiveness Analysis | Economics/Finance | Chronic Disease/Risk | Costing Methods | Health Outcomes | Evidence Synthesis | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Global Governance | Government/Law | Health/Medicine | Science/Technology | Global -
ReportPublication 2017Underestimated Cost of the Opioid Crisis
This report on the opioid public health crisis was released by the White House Council …
This report on the opioid public health crisis was released by the White House Council on Economic Advisors (CEA) in November 2017. It corrects previous estimates of related costs by adding the value of the associated deaths. Earlier estimates focused on medical and other expenditures, while the new report also includes estimates of the value that individuals place on reducing their own risks of premature mortality. The report notes that, in 2015, over 33,000 Americans…
Preferences/Values | Benefit-Cost Analysis | Economics/Finance | Chronic Disease/Risk | Costing Methods | Mental Health | Policy/Regulation | Government/Law | Health/Medicine | North America -
ArticlePublication 2017Cost-Effectiveness of Testing and Treatment for Latent TB
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve …
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. This analysis estimated health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities (e.g., diabetes, HIV infection, and end-stage renal disease). A decision analytic tree and Markov cohort simulation model was used to compare the following strategies: no testing, tuberculin skin test (TST), interferon gamma release assay…
Test Performance | Cost-Effectiveness Analysis | Economics/Finance | Chronic Disease/Risk | State-Transition | Microsimulation | Infectious Diseases | Health Systems | Health/Medicine | Global | North America